A Phase Ii Trial to Assess the Activity and Safety of the Hypoxia-Activated Prodrug Evofosfamide (Th-302) in Combination with Sunitinib in Patients with Disseminated Grade 1 and 2 Pancreatic Neuroendocrine Tumors (pnet) As A First-Line Approach: the Getne-1408 Trial.
Journal of clinical oncology（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined